Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 10/20 | 0.56 |
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etriciguat SCHEMBL419874 | 0.94 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Etriciguat SCHEMBL29388720 | 0.94 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174189 | 0.88 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174830 | 0.87 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6068522 | 0.87 | ADORA3 (0.49) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL27557251 | 0.86 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL7835258 | 0.86 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL16244821 | 0.85 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL175343 | 0.85 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6215423 | 0.85 | ADORA3 (0.53) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298055-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | ADORA3 3250/4885KCNH2 1074/4885PDE5A 12/4885 |
| US-20170298055-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG2 | ADORA3 930/4885KCNH2 191/4885PDE5A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.